Liquid biopsy for cancer management: a revolutionary but still limited new tool for precision medicine

The term liquid biopsy is used in contraposition to the traditional “solid” tissue biopsy. In the oncology field it has opened a new plethora of clinical opportunities as tumor-derived material is shedded into the different biofluids from where it can be isolated and analyzed. Common biofluids inclu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Arechederra María, Ávila Matías A., Berasain Carmen
Formato:	article
Lenguaje:	EN ES
Publicado:	De Gruyter 2020
Materias:	circulating biomarkers circulating tumor cells (ctcs) circulating tumor dna (ctdna) personalized medicine tumor circulome Medical technology R855-855.5
Acceso en línea:	https://doaj.org/article/a1932c4c5f234a1ab17ee4fb85f5779a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a1932c4c5f234a1ab17ee4fb85f5779a
record_format	dspace
spelling	oai:doaj.org-article:a1932c4c5f234a1ab17ee4fb85f5779a2021-12-05T14:10:38ZLiquid biopsy for cancer management: a revolutionary but still limited new tool for precision medicine2628-491X10.1515/almed-2020-0009https://doaj.org/article/a1932c4c5f234a1ab17ee4fb85f5779a2020-04-01T00:00:00Zhttps://doi.org/10.1515/almed-2020-0009https://doaj.org/toc/2628-491XThe term liquid biopsy is used in contraposition to the traditional “solid” tissue biopsy. In the oncology field it has opened a new plethora of clinical opportunities as tumor-derived material is shedded into the different biofluids from where it can be isolated and analyzed. Common biofluids include blood, urine, saliva, cerebrospinal fluid (CSF), pleural effusion or bile. Starting from these biological specimens several analytes can be isolated, among which we will review the most widely used: circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), circulating tumor RNA (ctRNA), proteins, metabolites, and exosomes. Regarding the nature of the biomarkers it will depend on the analyte, the type of tumor and the clinical application of the liquid biopsy and it includes, somatic point mutations, deletions, amplifications, gene-fusions, DNA-methylated marks, tumor-specific miRNAs, proteins or metabolites. Here we review the characteristics of the analytes and the methodologies used for their isolation. We also describe the applications of the liquid biopsy in the management of patients with cancer, from the early detection of cancers to treatment guidance in patients with advanced tumors. Finally, we also discuss some current limitations and still open questions.Arechederra MaríaÁvila Matías A.Berasain CarmenDe Gruyterarticlecirculating biomarkerscirculating tumor cells (ctcs)circulating tumor dna (ctdna)personalized medicinetumor circulomeMedical technologyR855-855.5ENESAdvances in Laboratory Medicine, Vol 1, Iss 3, Pp 140-6 (2020)
institution	DOAJ
collection	DOAJ
language	EN ES
topic	circulating biomarkers circulating tumor cells (ctcs) circulating tumor dna (ctdna) personalized medicine tumor circulome Medical technology R855-855.5
spellingShingle	circulating biomarkers circulating tumor cells (ctcs) circulating tumor dna (ctdna) personalized medicine tumor circulome Medical technology R855-855.5 Arechederra María Ávila Matías A. Berasain Carmen Liquid biopsy for cancer management: a revolutionary but still limited new tool for precision medicine
description	The term liquid biopsy is used in contraposition to the traditional “solid” tissue biopsy. In the oncology field it has opened a new plethora of clinical opportunities as tumor-derived material is shedded into the different biofluids from where it can be isolated and analyzed. Common biofluids include blood, urine, saliva, cerebrospinal fluid (CSF), pleural effusion or bile. Starting from these biological specimens several analytes can be isolated, among which we will review the most widely used: circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), circulating tumor RNA (ctRNA), proteins, metabolites, and exosomes. Regarding the nature of the biomarkers it will depend on the analyte, the type of tumor and the clinical application of the liquid biopsy and it includes, somatic point mutations, deletions, amplifications, gene-fusions, DNA-methylated marks, tumor-specific miRNAs, proteins or metabolites. Here we review the characteristics of the analytes and the methodologies used for their isolation. We also describe the applications of the liquid biopsy in the management of patients with cancer, from the early detection of cancers to treatment guidance in patients with advanced tumors. Finally, we also discuss some current limitations and still open questions.
format	article
author	Arechederra María Ávila Matías A. Berasain Carmen
author_facet	Arechederra María Ávila Matías A. Berasain Carmen
author_sort	Arechederra María
title	Liquid biopsy for cancer management: a revolutionary but still limited new tool for precision medicine
title_short	Liquid biopsy for cancer management: a revolutionary but still limited new tool for precision medicine
title_full	Liquid biopsy for cancer management: a revolutionary but still limited new tool for precision medicine
title_fullStr	Liquid biopsy for cancer management: a revolutionary but still limited new tool for precision medicine
title_full_unstemmed	Liquid biopsy for cancer management: a revolutionary but still limited new tool for precision medicine
title_sort	liquid biopsy for cancer management: a revolutionary but still limited new tool for precision medicine
publisher	De Gruyter
publishDate	2020
url	https://doaj.org/article/a1932c4c5f234a1ab17ee4fb85f5779a
work_keys_str_mv	AT arechederramaria liquidbiopsyforcancermanagementarevolutionarybutstilllimitednewtoolforprecisionmedicine AT avilamatiasa liquidbiopsyforcancermanagementarevolutionarybutstilllimitednewtoolforprecisionmedicine AT berasaincarmen liquidbiopsyforcancermanagementarevolutionarybutstilllimitednewtoolforprecisionmedicine
_version_	1718371856258433024

Liquid biopsy for cancer management: a revolutionary but still limited new tool for precision medicine

Ejemplares similares